Rituximab and Belimumab for Lupus Nephritis

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 9, 2015

Primary Completion Date

March 12, 2018

Study Completion Date

February 8, 2019

Conditions
Lupus Nephritis
Interventions
BIOLOGICAL

Rituximab

Rituximab 1000mg intravenously (IV) at week 0 and week 2

DRUG

Cyclophosphamide

Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.

DRUG

Prednisone

"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"

DRUG

Methylprednisolone

"Week 0 and Week 2:~Solumedrol (100 mg) IV"

DRUG

Diphenhydramine

Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

DRUG

Acetaminophen

Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

BIOLOGICAL

Rituximab

Rituximab 1000mg intravenously (IV) at week 0 and week 2.

DRUG

Cyclophosphamide

Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.

DRUG

Prednisone

"* Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)~* Continue prednisone 10 mg/day to week 96"

DRUG

Methylprednisolone

Week 0 and Week 2: Solumedrol (100 mg) IV

DRUG

Diphenhydramine

Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

DRUG

Acetaminophen

Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.

BIOLOGICAL

Belimumab

The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48

Trial Locations (15)

10016

New York University, Langone Medical Center, New York

10021

Weill Cornell Medical College: Hospital for Special Surgery -, New York

10030

Feinstein Institute, North Shore Hospital, Manhasset

10032

Columbia University Medical Center, New York

27599

University of North Carolina School of Medicine:, Chapel Hill

29425

Medical University of South Carolina, Charleston

30303

Emory University School of Medicine, Atlanta

35294

University of Alabama, Birmingham, Birmingham

36110

Washington University in St. Louis, St Louis

43213

Ohio State University Wexner Medical Center:, Columbus

75390

University of Texas Southwestern, Dallas

80045

University of Colorado Denver: School of Medicine: Division of Rheumatology, Aurora

80218

Colorado Kidney Care, Denver

90095

UCLA Medical Center: Division of Rheumatology, Los Angeles

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Immune Tolerance Network (ITN)

NETWORK

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02260934 - Rituximab and Belimumab for Lupus Nephritis | Biotech Hunter | Biotech Hunter